Microviable Therapeutics is in process of developing a kit designed for the collection, storage and transport of fecal samples. This will allow processing intestinal microbiota in a way that long-term viability will be ensured. Currently, we also have a catalog of different services related to microbiota analisis. Further information is provided using the contact form at the bottom of this site.
We are developing different products, based on viable and well-characterised gut microbiota, focused on the restauration of the intestinal ecosystem after disrupting treatments, such as prolonged antibiotic intake or pelvic radiotherapy. We are also developing biotherapeutics for the treatment in which an altered microbiota is detected.
Microviable Therapeutics SL is integrated by a multidisciplinary team of researchers with expertise in intestinal microbiota and human health, as well as experts in marketing, business and administration. In addition, we have a network of collaborators in different hospitals, universities and research centers, both at national and international levels.
Responsible of R+D+I. Noelia obtained her PhD in the University of Oviedo. She has been postdoctoral researcher of the IPLA-CSIC between 2008-2016. She has experience in fast microorganism detection by culture-independent techniques, molecular biology, genetic engeering, proteomics and transcriptomics.
Senior researcher at the IPLA-CSIC; permanent staff. He obtained his PhD in the University of Santiago de Compostela. His main research lines are focused in understanding the relationship of the human intestinal microbiota with health and diet.
Postdoctoral researcher at the IPLA-CSIC, she obtained her PhD by the University of Oviedo. Her PhD work consisted on the analysis of healthy intestinal microbiotas. From them, she has worked in different institutions in research lines related to the factors conditioned the appearance of intestinal dysbiosis in humans.
Borja defended his PhD in the University of Oviedo; he is senior researcher and permanent staff at the IPLA-CSIC. His main research line is devoted to the understand the molecular mechanisms of host-bacteria interaction through extracellular and surface-associated proteins/peptides, with the application of omics and bioinformatics. More info .
Postdoctoral researcher of the IPLA-CSIC and located at the University Hospital of Asturias. He has experience in probiotic characterization and in metabolism/physiology of representatives of the human gut microbiota. He is currently studying the response of the immune system to certain surface-associated proteins from probiotic bacteria.